Literature DB >> 20409594

Elevated plasma C4a levels in multiple sclerosis correlate with disease activity.

Gillian Ingram1, Svetlana Hakobyan, Neil P Robertson, B Paul Morgan.   

Abstract

Complement plays a pivotal role in the pathogenesis of multiple sclerosis. C4a, an activated fragment of complement component C4, has been linked to disease activity. We correlated plasma C4 and plasma and CSF C4a with clinical disease in a well-characterised cohort of patients and controls. Plasma C4 was non-significantly and CSF C4a was significantly elevated overall in patients compared to controls. Plasma C4a was raised only in acute relapse, decreasing over 2 months. Results demonstrate intrathecal and systemic activation of complement, reflected in changes in CSF and plasma C4a. The data support a role for complement activation in pathogenesis and suggest a systemic component to the disease. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20409594     DOI: 10.1016/j.jneuroim.2010.03.014

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Plasma Protein Levels Analysis in Multiple Sclerosis Sardinian Families Identified C9 and CYP24A1 as Candidate Biomarkers.

Authors:  Andrea Nova; Teresa Fazia; Ashley Beecham; Valeria Saddi; Marialuisa Piras; Jacob L McCauley; Carlo Berzuini; Luisa Bernardinelli
Journal:  Life (Basel)       Date:  2022-01-20

Review 2.  The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Authors:  Alexandru Tatomir; Anamaria Talpos-Caia; Freidrich Anselmo; Adam M Kruszewski; Dallas Boodhoo; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

3.  Systemic complement profiling in multiple sclerosis as a biomarker of disease state.

Authors:  G Ingram; S Hakobyan; C L Hirst; C L Harris; S Loveless; J P Mitchell; T P Pickersgill; N P Robertson; B P Morgan
Journal:  Mult Scler       Date:  2012-02-21       Impact factor: 6.312

4.  Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis.

Authors:  Lionel Blanchet; Agnieszka Smolinska; Amos Attali; Marcel P Stoop; Kirsten A M Ampt; Hans van Aken; Ernst Suidgeest; Tinka Tuinstra; Sybren S Wijmenga; Theo Luider; Lutgarde M C Buydens
Journal:  BMC Bioinformatics       Date:  2011-06-22       Impact factor: 3.169

5.  Differences in the Plasma Proteome of Patients with Hypothyroidism before and after Thyroid Hormone Replacement: A Proteomic Analysis.

Authors:  Assim A Alfadda; Hicham Benabdelkamel; Afshan Masood; Anwar A Jammah; Aishah A Ekhzaimy
Journal:  Int J Mol Sci       Date:  2018-01-01       Impact factor: 5.923

Review 6.  An "Outside-In" and "Inside-Out" Consideration of Complement in the Multiple Sclerosis Brain: Lessons From Development and Neurodegenerative Diseases.

Authors:  B Paul Morgan; Jennifer L Gommerman; Valeria Ramaglia
Journal:  Front Cell Neurosci       Date:  2021-01-07       Impact factor: 5.505

Review 7.  The Role of Complement in Synaptic Pruning and Neurodegeneration.

Authors:  Angela Gomez-Arboledas; Munjal M Acharya; Andrea J Tenner
Journal:  Immunotargets Ther       Date:  2021-09-24

Review 8.  The role of the complement system in Multiple Sclerosis: A review.

Authors:  Nil Saez-Calveras; Olaf Stuve
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

Review 9.  Complement in neurological disorders and emerging complement-targeted therapeutics.

Authors:  Marinos C Dalakas; Harry Alexopoulos; Peter J Spaeth
Journal:  Nat Rev Neurol       Date:  2020-10-01       Impact factor: 42.937

10.  The plasma peptides of Alzheimer's disease.

Authors:  Angelique Florentinus-Mefailoski; Peter Bowden; Philip Scheltens; Joep Killestein; Charlotte Teunissen; John G Marshall
Journal:  Clin Proteomics       Date:  2021-06-28       Impact factor: 3.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.